Skip to main content
NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
30.77
+0.91 (3.05%)
At close: Mar 9, 2026, 4:00 PM EDT
28.99
-1.78 (-5.80%)
After-hours: Mar 9, 2026, 7:46 PM EDT

NAMS Revenue

In the year 2025, NewAmsterdam Pharma Company had annual revenue of $22.50M, down -50.61%. NewAmsterdam Pharma Company had revenue of $32.00K in the quarter ending December 31, 2025, a decrease of -99.75%.

Revenue (ttm)
$22.50M
Revenue Growth
-50.61%
P/S Ratio
157.21
Revenue / Employee
$225,030
Employees
100
Market Cap
3.54B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202522.50M-23.06M-50.61%
Dec 31, 202445.56M31.47M223.37%
Dec 31, 202314.09M-88.60M-86.28%
Dec 31, 2022102.69M--
Dec 31, 2021---
Dec 31, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
ACADIA Pharmaceuticals 1.07B
Legend Biotech 909.05M
Corcept Therapeutics 761.41M
ADMA Biologics 510.17M
Tarsus Pharmaceuticals 451.36M
Centessa Pharmaceuticals 15.00M
Xenon Pharmaceuticals 7.50M
Revenue Rankings

NAMS News

More News